Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Technology Assessment, Biomedical | 4 | 2023 | 307 | 0.980 |
Why?
|
Cost-Benefit Analysis | 23 | 2023 | 5385 | 0.960 |
Why?
|
Medical Records Systems, Computerized | 24 | 2005 | 1204 | 0.930 |
Why?
|
Models, Economic | 8 | 2021 | 713 | 0.560 |
Why?
|
Muscular Atrophy, Spinal | 1 | 2019 | 258 | 0.550 |
Why?
|
Evidence-Based Medicine | 10 | 2017 | 3611 | 0.460 |
Why?
|
Confidentiality | 9 | 1998 | 609 | 0.430 |
Why?
|
Prediabetic State | 1 | 2016 | 493 | 0.390 |
Why?
|
Diabetes Mellitus, Type 2 | 5 | 2021 | 11695 | 0.360 |
Why?
|
Glucagon-Like Peptides | 2 | 2021 | 124 | 0.360 |
Why?
|
Hemophilia A | 2 | 2023 | 351 | 0.330 |
Why?
|
Practice Guidelines as Topic | 13 | 2017 | 7276 | 0.300 |
Why?
|
Asthma | 2 | 2022 | 5955 | 0.270 |
Why?
|
Computer Communication Networks | 6 | 1998 | 295 | 0.270 |
Why?
|
HIV Protease Inhibitors | 1 | 2007 | 430 | 0.250 |
Why?
|
Reverse Transcriptase Inhibitors | 1 | 2007 | 615 | 0.240 |
Why?
|
Leukodystrophy, Metachromatic | 1 | 2024 | 42 | 0.230 |
Why?
|
Quality-Adjusted Life Years | 7 | 2022 | 1679 | 0.230 |
Why?
|
Dermatitis, Atopic | 2 | 2022 | 653 | 0.220 |
Why?
|
Drug Costs | 5 | 2021 | 1104 | 0.220 |
Why?
|
Retinal Diseases | 2 | 2019 | 683 | 0.220 |
Why?
|
Reminder Systems | 5 | 1996 | 370 | 0.220 |
Why?
|
Needle-Exchange Programs | 1 | 2022 | 25 | 0.220 |
Why?
|
Mass Screening | 2 | 2017 | 5238 | 0.210 |
Why?
|
Review Literature as Topic | 2 | 2017 | 333 | 0.210 |
Why?
|
BCG Vaccine | 2 | 2022 | 367 | 0.210 |
Why?
|
Diabetic Retinopathy | 1 | 2010 | 1205 | 0.200 |
Why?
|
Drug Therapy, Computer-Assisted | 2 | 1994 | 203 | 0.190 |
Why?
|
Serotonin 5-HT1 Receptor Agonists | 1 | 2020 | 46 | 0.190 |
Why?
|
Pregnenediones | 1 | 2020 | 29 | 0.190 |
Why?
|
beta-Thalassemia | 1 | 2022 | 225 | 0.180 |
Why?
|
Computer Systems | 6 | 1997 | 483 | 0.180 |
Why?
|
Anti-Obesity Agents | 1 | 2023 | 215 | 0.180 |
Why?
|
Online Systems | 2 | 2001 | 184 | 0.180 |
Why?
|
Receptors, Serotonin | 1 | 2020 | 210 | 0.180 |
Why?
|
Treatment Outcome | 17 | 2023 | 62966 | 0.180 |
Why?
|
California | 2 | 2023 | 1400 | 0.170 |
Why?
|
Evaluation Studies as Topic | 4 | 1997 | 1676 | 0.170 |
Why?
|
Urinary Bladder Neoplasms | 2 | 2022 | 2229 | 0.170 |
Why?
|
Guideline Adherence | 3 | 2017 | 2266 | 0.170 |
Why?
|
Antibodies, Bispecific | 1 | 2021 | 164 | 0.170 |
Why?
|
cis-trans-Isomerases | 1 | 2018 | 44 | 0.170 |
Why?
|
Dystrophin | 1 | 2020 | 285 | 0.160 |
Why?
|
Emollients | 1 | 2018 | 33 | 0.160 |
Why?
|
Hypoglycemic Agents | 2 | 2021 | 2866 | 0.160 |
Why?
|
Calcitonin Gene-Related Peptide | 1 | 2020 | 305 | 0.160 |
Why?
|
Massachusetts | 3 | 2022 | 8662 | 0.160 |
Why?
|
Computer Security | 7 | 1998 | 263 | 0.160 |
Why?
|
Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2021 | 437 | 0.150 |
Why?
|
Oligonucleotides, Antisense | 1 | 2020 | 433 | 0.150 |
Why?
|
Decision Making, Computer-Assisted | 2 | 1995 | 150 | 0.150 |
Why?
|
Muscular Dystrophy, Duchenne | 1 | 2020 | 256 | 0.150 |
Why?
|
Clinical Protocols | 2 | 2014 | 1459 | 0.150 |
Why?
|
Alzheimer Disease | 3 | 2023 | 7988 | 0.150 |
Why?
|
Humans | 71 | 2024 | 742088 | 0.150 |
Why?
|
Creatinine | 2 | 1994 | 1916 | 0.150 |
Why?
|
Hospital Information Systems | 9 | 1998 | 395 | 0.140 |
Why?
|
Minority Groups | 1 | 2023 | 1215 | 0.130 |
Why?
|
Anemia, Sickle Cell | 1 | 2023 | 1017 | 0.130 |
Why?
|
Blood Coagulation | 1 | 2021 | 1126 | 0.130 |
Why?
|
Internet | 3 | 2008 | 3062 | 0.130 |
Why?
|
Anti-Asthmatic Agents | 1 | 2019 | 533 | 0.120 |
Why?
|
United States | 16 | 2023 | 69693 | 0.120 |
Why?
|
Clinical Medicine | 2 | 1993 | 147 | 0.120 |
Why?
|
Asymptomatic Diseases | 1 | 2016 | 552 | 0.110 |
Why?
|
Analgesics | 1 | 2020 | 1037 | 0.110 |
Why?
|
Clinical Laboratory Information Systems | 1 | 1994 | 108 | 0.110 |
Why?
|
Glucose Tolerance Test | 1 | 2016 | 1150 | 0.110 |
Why?
|
Antibodies, Monoclonal | 2 | 2022 | 9274 | 0.110 |
Why?
|
Cardiomyopathy, Hypertrophic | 1 | 2022 | 1263 | 0.110 |
Why?
|
Amyotrophic Lateral Sclerosis | 1 | 2023 | 1421 | 0.100 |
Why?
|
Cystic Fibrosis | 1 | 2021 | 1178 | 0.100 |
Why?
|
Attitude to Computers | 1 | 1993 | 202 | 0.100 |
Why?
|
Quality Assurance, Health Care | 3 | 2013 | 2211 | 0.100 |
Why?
|
Biological Products | 1 | 2019 | 856 | 0.090 |
Why?
|
Idiopathic Pulmonary Fibrosis | 1 | 2015 | 451 | 0.090 |
Why?
|
Glucocorticoids | 1 | 2019 | 2107 | 0.090 |
Why?
|
Information Dissemination | 1 | 1997 | 1100 | 0.080 |
Why?
|
Migraine Disorders | 1 | 2020 | 1620 | 0.080 |
Why?
|
Decision Support Systems, Clinical | 1 | 2017 | 1162 | 0.080 |
Why?
|
Sample Size | 1 | 2011 | 844 | 0.080 |
Why?
|
Obesity | 2 | 2023 | 12705 | 0.080 |
Why?
|
Human Rights | 1 | 1990 | 302 | 0.080 |
Why?
|
Alleles | 1 | 2018 | 6931 | 0.070 |
Why?
|
Clinical Trials as Topic | 1 | 2023 | 7901 | 0.070 |
Why?
|
Immunosuppressive Agents | 1 | 2020 | 4147 | 0.070 |
Why?
|
Health Personnel | 3 | 2016 | 3210 | 0.070 |
Why?
|
Medical Record Linkage | 3 | 1998 | 284 | 0.070 |
Why?
|
Myocardial Infarction | 1 | 2007 | 11690 | 0.070 |
Why?
|
HIV Infections | 5 | 2007 | 16678 | 0.070 |
Why?
|
Information Systems | 1 | 2008 | 410 | 0.070 |
Why?
|
Observer Variation | 1 | 2011 | 2593 | 0.060 |
Why?
|
Markov Chains | 2 | 2018 | 969 | 0.060 |
Why?
|
Patients | 2 | 2005 | 892 | 0.060 |
Why?
|
Boston | 12 | 2003 | 9305 | 0.060 |
Why?
|
Health Policy | 3 | 2022 | 2657 | 0.060 |
Why?
|
Education, Medical | 1 | 2016 | 1717 | 0.060 |
Why?
|
Meta-Analysis as Topic | 2 | 2023 | 1342 | 0.060 |
Why?
|
Drug Approval | 2 | 2021 | 740 | 0.060 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2020 | 9941 | 0.050 |
Why?
|
Software Design | 3 | 1998 | 176 | 0.050 |
Why?
|
Aged | 7 | 2023 | 162944 | 0.050 |
Why?
|
Transaminases | 1 | 2003 | 199 | 0.050 |
Why?
|
Risk | 3 | 2011 | 9679 | 0.050 |
Why?
|
Therapy, Computer-Assisted | 2 | 1996 | 277 | 0.050 |
Why?
|
Cross-Sectional Studies | 1 | 2023 | 24913 | 0.050 |
Why?
|
United States Food and Drug Administration | 2 | 2021 | 1581 | 0.050 |
Why?
|
Rhode Island | 1 | 2022 | 347 | 0.050 |
Why?
|
Acute Kidney Injury | 1 | 1994 | 1967 | 0.050 |
Why?
|
Academies and Institutes | 1 | 2023 | 317 | 0.050 |
Why?
|
Ambulatory Care Information Systems | 2 | 1991 | 86 | 0.050 |
Why?
|
Health Care Costs | 1 | 1994 | 3203 | 0.050 |
Why?
|
Benzylamines | 1 | 2022 | 226 | 0.050 |
Why?
|
Informed Consent | 2 | 1998 | 991 | 0.050 |
Why?
|
Uracil | 1 | 2022 | 164 | 0.050 |
Why?
|
Creatine Kinase | 1 | 2003 | 694 | 0.050 |
Why?
|
Benzodioxoles | 1 | 2021 | 69 | 0.050 |
Why?
|
Aminophenols | 1 | 2021 | 78 | 0.050 |
Why?
|
Hospitals, Teaching | 4 | 1993 | 1179 | 0.050 |
Why?
|
Adenosine Monophosphate | 1 | 2022 | 276 | 0.040 |
Why?
|
Primary Health Care | 6 | 2005 | 4551 | 0.040 |
Why?
|
Drug Therapy, Combination | 2 | 2021 | 6483 | 0.040 |
Why?
|
Alanine | 1 | 2022 | 572 | 0.040 |
Why?
|
Kidney Diseases | 1 | 1991 | 2145 | 0.040 |
Why?
|
Antineoplastic Agents | 1 | 2022 | 13655 | 0.040 |
Why?
|
Cost Savings | 2 | 2022 | 925 | 0.040 |
Why?
|
Hospitals | 2 | 2008 | 3937 | 0.040 |
Why?
|
Medical Informatics Computing | 1 | 1998 | 25 | 0.040 |
Why?
|
Pyridines | 2 | 2021 | 2818 | 0.040 |
Why?
|
Factor VIII | 1 | 2021 | 348 | 0.040 |
Why?
|
Unified Medical Language System | 1 | 1998 | 86 | 0.040 |
Why?
|
Interleukin-4 Receptor alpha Subunit | 1 | 2018 | 45 | 0.040 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2013 | 3038 | 0.040 |
Why?
|
Emergency Service, Hospital | 1 | 1997 | 7645 | 0.040 |
Why?
|
Paper | 1 | 1998 | 85 | 0.040 |
Why?
|
Home Nursing | 1 | 1998 | 92 | 0.040 |
Why?
|
Quinolones | 1 | 2021 | 366 | 0.040 |
Why?
|
Aminopyridines | 1 | 2021 | 541 | 0.040 |
Why?
|
Oligonucleotides | 1 | 2020 | 572 | 0.040 |
Why?
|
Injections, Subcutaneous | 1 | 2018 | 664 | 0.040 |
Why?
|
Age Factors | 2 | 2019 | 18355 | 0.040 |
Why?
|
Clinical Competence | 2 | 2012 | 4681 | 0.040 |
Why?
|
Female | 13 | 2023 | 379592 | 0.040 |
Why?
|
Adult | 9 | 2021 | 213712 | 0.030 |
Why?
|
Administration, Inhalation | 1 | 2019 | 1104 | 0.030 |
Why?
|
Blood Transfusion | 1 | 2022 | 1296 | 0.030 |
Why?
|
Quinolines | 1 | 2021 | 719 | 0.030 |
Why?
|
Confidence Intervals | 2 | 2012 | 2970 | 0.030 |
Why?
|
Maryland | 1 | 1996 | 276 | 0.030 |
Why?
|
Diffusion of Innovation | 1 | 2001 | 725 | 0.030 |
Why?
|
Anticholesteremic Agents | 1 | 2003 | 979 | 0.030 |
Why?
|
Drug Combinations | 1 | 2021 | 1961 | 0.030 |
Why?
|
Prednisone | 1 | 2020 | 1567 | 0.030 |
Why?
|
Medical Records, Problem-Oriented | 1 | 1995 | 35 | 0.030 |
Why?
|
Hospital Records | 1 | 1995 | 95 | 0.030 |
Why?
|
Patient Advocacy | 1 | 1997 | 353 | 0.030 |
Why?
|
Office Automation | 1 | 1994 | 14 | 0.030 |
Why?
|
Benzamides | 1 | 2020 | 1378 | 0.030 |
Why?
|
Expert Systems | 1 | 1995 | 81 | 0.030 |
Why?
|
Outpatient Clinics, Hospital | 2 | 2001 | 392 | 0.030 |
Why?
|
User-Computer Interface | 3 | 1997 | 1426 | 0.030 |
Why?
|
Crime | 1 | 1996 | 215 | 0.030 |
Why?
|
Social Responsibility | 1 | 1997 | 389 | 0.030 |
Why?
|
Software | 3 | 1998 | 4434 | 0.030 |
Why?
|
Pyrroles | 1 | 2020 | 1143 | 0.030 |
Why?
|
Exons | 1 | 2020 | 2431 | 0.030 |
Why?
|
Disease Progression | 1 | 2010 | 13256 | 0.030 |
Why?
|
Male | 12 | 2021 | 349538 | 0.030 |
Why?
|
Medical Records | 2 | 1998 | 1413 | 0.030 |
Why?
|
Internal Medicine | 1 | 2000 | 1009 | 0.030 |
Why?
|
Information Storage and Retrieval | 2 | 1998 | 824 | 0.030 |
Why?
|
Economic Competition | 1 | 1994 | 214 | 0.030 |
Why?
|
Administration, Oral | 1 | 2020 | 3913 | 0.030 |
Why?
|
Organizational Policy | 1 | 1995 | 427 | 0.030 |
Why?
|
Indoles | 1 | 2021 | 1834 | 0.030 |
Why?
|
Computers | 1 | 1995 | 611 | 0.030 |
Why?
|
Piperidines | 1 | 2020 | 1602 | 0.030 |
Why?
|
Vision Disorders | 1 | 2018 | 1057 | 0.020 |
Why?
|
Medical History Taking | 1 | 1995 | 783 | 0.020 |
Why?
|
Germany | 1 | 2013 | 860 | 0.020 |
Why?
|
Severity of Illness Index | 2 | 2019 | 15530 | 0.020 |
Why?
|
Cardiovascular Diseases | 1 | 2016 | 15108 | 0.020 |
Why?
|
Natural Language Processing | 1 | 1998 | 1035 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 1998 | 1503 | 0.020 |
Why?
|
Pyrazoles | 1 | 2021 | 1970 | 0.020 |
Why?
|
Aminoglycosides | 1 | 1991 | 161 | 0.020 |
Why?
|
Publication Bias | 1 | 2010 | 161 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2018 | 4929 | 0.020 |
Why?
|
Acquired Immunodeficiency Syndrome | 2 | 1996 | 2231 | 0.020 |
Why?
|
Young Adult | 3 | 2021 | 56350 | 0.020 |
Why?
|
Personal Health Services | 1 | 2008 | 25 | 0.020 |
Why?
|
Biomedical Technology | 1 | 2010 | 221 | 0.020 |
Why?
|
Research Design | 2 | 2013 | 5979 | 0.020 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2003 | 3239 | 0.020 |
Why?
|
Adolescent | 3 | 2021 | 85649 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2001 | 3527 | 0.020 |
Why?
|
Interviews as Topic | 1 | 1995 | 2536 | 0.020 |
Why?
|
Canada | 1 | 2013 | 2061 | 0.020 |
Why?
|
Immunotherapy | 1 | 2022 | 4414 | 0.020 |
Why?
|
Treatment Failure | 1 | 2013 | 2615 | 0.020 |
Why?
|
Information Services | 1 | 2008 | 244 | 0.020 |
Why?
|
Epidemiologic Methods | 1 | 2012 | 1364 | 0.020 |
Why?
|
Knowledge | 1 | 2008 | 179 | 0.020 |
Why?
|
Diagnosis-Related Groups | 1 | 2008 | 454 | 0.020 |
Why?
|
Attitude of Health Personnel | 3 | 1995 | 3839 | 0.020 |
Why?
|
Attitude | 1 | 1990 | 772 | 0.020 |
Why?
|
Artificial Intelligence | 2 | 1996 | 2187 | 0.020 |
Why?
|
Middle Aged | 6 | 2021 | 213127 | 0.020 |
Why?
|
CD4 Lymphocyte Count | 3 | 1996 | 2557 | 0.020 |
Why?
|
Academic Medical Centers | 3 | 2001 | 2749 | 0.020 |
Why?
|
Cost of Illness | 1 | 1994 | 1852 | 0.020 |
Why?
|
Data Interpretation, Statistical | 1 | 1995 | 2714 | 0.020 |
Why?
|
Medical Audit | 1 | 2005 | 467 | 0.010 |
Why?
|
Patient Care Team | 1 | 1995 | 2527 | 0.010 |
Why?
|
Linear Models | 1 | 1994 | 5948 | 0.010 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 1991 | 1517 | 0.010 |
Why?
|
Quality of Health Care | 2 | 2016 | 4369 | 0.010 |
Why?
|
Societies, Medical | 1 | 2015 | 3740 | 0.010 |
Why?
|
Monitoring, Physiologic | 1 | 1991 | 1737 | 0.010 |
Why?
|
Physicians | 4 | 1995 | 4554 | 0.010 |
Why?
|
Aged, 80 and over | 3 | 2021 | 57683 | 0.010 |
Why?
|
Child | 2 | 2021 | 77478 | 0.010 |
Why?
|
Decision Making | 1 | 2016 | 3869 | 0.010 |
Why?
|
Aspartate Aminotransferases | 1 | 2003 | 418 | 0.010 |
Why?
|
Hospital Bed Capacity, 500 and over | 2 | 1991 | 115 | 0.010 |
Why?
|
Time Factors | 2 | 2020 | 40054 | 0.010 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 1991 | 2276 | 0.010 |
Why?
|
Alanine Transaminase | 1 | 2003 | 592 | 0.010 |
Why?
|
Palpation | 1 | 2000 | 166 | 0.010 |
Why?
|
Decision Support Techniques | 1 | 1990 | 1952 | 0.010 |
Why?
|
Prospective Studies | 3 | 1995 | 53187 | 0.010 |
Why?
|
Diabetes Mellitus | 1 | 1998 | 5724 | 0.010 |
Why?
|
Pilot Projects | 2 | 2005 | 8297 | 0.010 |
Why?
|
Muscular Diseases | 1 | 2003 | 557 | 0.010 |
Why?
|
Hospitalization | 2 | 1995 | 10232 | 0.010 |
Why?
|
Quality Indicators, Health Care | 1 | 2008 | 1831 | 0.010 |
Why?
|
Organizational Innovation | 1 | 2001 | 559 | 0.010 |
Why?
|
Signal Transduction | 1 | 2020 | 23387 | 0.010 |
Why?
|
Reproducibility of Results | 2 | 2010 | 19862 | 0.010 |
Why?
|
Mutation | 1 | 2021 | 29717 | 0.010 |
Why?
|
Systems Integration | 1 | 1998 | 440 | 0.010 |
Why?
|
Data Collection | 2 | 1996 | 3339 | 0.010 |
Why?
|
Organizational Objectives | 1 | 1998 | 438 | 0.010 |
Why?
|
Computer Literacy | 1 | 1995 | 43 | 0.010 |
Why?
|
Semantics | 1 | 1998 | 584 | 0.010 |
Why?
|
Vocabulary, Controlled | 1 | 1996 | 170 | 0.010 |
Why?
|
Length of Stay | 1 | 2008 | 6294 | 0.010 |
Why?
|
Methods | 1 | 1995 | 1128 | 0.010 |
Why?
|
Hospital Mortality | 1 | 2008 | 5310 | 0.010 |
Why?
|
Health Planning | 1 | 1996 | 237 | 0.010 |
Why?
|
Famous Persons | 1 | 1995 | 108 | 0.010 |
Why?
|
Breast Neoplasms | 1 | 2000 | 20774 | 0.010 |
Why?
|
Zidovudine | 1 | 1995 | 620 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 1991 | 7153 | 0.010 |
Why?
|
Family Practice | 1 | 1995 | 516 | 0.010 |
Why?
|
Policy Making | 1 | 1996 | 554 | 0.010 |
Why?
|
Risk Assessment | 1 | 2013 | 23320 | 0.010 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 1995 | 654 | 0.010 |
Why?
|
Activities of Daily Living | 1 | 2000 | 2414 | 0.010 |
Why?
|
Guidelines as Topic | 1 | 1997 | 1402 | 0.010 |
Why?
|
Medicare | 1 | 2008 | 6532 | 0.010 |
Why?
|
Mammography | 1 | 2000 | 2474 | 0.010 |
Why?
|
Disclosure | 1 | 1995 | 736 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 1995 | 2885 | 0.010 |
Why?
|
Interprofessional Relations | 1 | 1995 | 1008 | 0.010 |
Why?
|
Retrospective Studies | 3 | 2003 | 77098 | 0.010 |
Why?
|
Employment | 1 | 1995 | 1124 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2005 | 21719 | 0.000 |
Why?
|
Liver | 1 | 2003 | 7470 | 0.000 |
Why?
|
Sex Factors | 1 | 2000 | 10392 | 0.000 |
Why?
|
Comorbidity | 1 | 2000 | 10372 | 0.000 |
Why?
|
Regression Analysis | 1 | 1995 | 6452 | 0.000 |
Why?
|
Nurses | 1 | 1995 | 2459 | 0.000 |
Why?
|
Physician-Patient Relations | 1 | 1998 | 3215 | 0.000 |
Why?
|
Ambulatory Care | 1 | 1995 | 2706 | 0.000 |
Why?
|
Communication | 1 | 1998 | 3728 | 0.000 |
Why?
|
Emergency Medical Services | 1 | 1995 | 1914 | 0.000 |
Why?
|
Cohort Studies | 1 | 2005 | 40450 | 0.000 |
Why?
|
Antiviral Agents | 1 | 1995 | 2978 | 0.000 |
Why?
|
Telemedicine | 1 | 1998 | 2853 | 0.000 |
Why?
|
Survival Rate | 1 | 1995 | 12773 | 0.000 |
Why?
|
Risk Factors | 1 | 1996 | 72145 | 0.000 |
Why?
|